Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
doi:10.1080/02763869.2019.1588072 18
TB-500 10mg Summary Description: TB-500 is a synthetic heptapeptide analog of the actin-binding motif of thymosin ?4 (T?4), composed of the acetylated sequence Ac-LKKTETQ
Most patients taking these medications maintain good vision with appropriate care
Koole, C., Savage, E
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
US$ 21.92
US$ 29.96
US$ 29.73
US$ 23.96
US$ 28.08
US$ 23.80
US$ 29.95
US$ 28.81
